Stealth BioTherapeutics Corp (NASDAQ:MITO) Expected to Post Earnings of -$0.07 Per Share

Share on StockTwits

Analysts expect Stealth BioTherapeutics Corp (NASDAQ:MITO) to announce ($0.07) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Stealth BioTherapeutics’ earnings. The company is scheduled to report its next earnings report on Wednesday, August 21st.

On average, analysts expect that Stealth BioTherapeutics will report full year earnings of ($0.26) per share for the current year. For the next fiscal year, analysts anticipate that the company will report earnings of ($0.22) per share. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that cover Stealth BioTherapeutics.

Stealth BioTherapeutics (NASDAQ:MITO) last issued its earnings results on Wednesday, May 15th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.14.

Several analysts have recently commented on MITO shares. HC Wainwright set a $5.00 price target on shares of Eyepoint Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, July 12th. Zacks Investment Research lowered shares of Hallmark Financial Services from a “buy” rating to a “hold” rating in a research report on Thursday. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $24.83.

Shares of MITO stock traded up $0.03 during trading hours on Wednesday, hitting $11.38. The company’s stock had a trading volume of 680 shares, compared to its average volume of 3,259. The stock has a fifty day moving average of $12.38. The firm has a market capitalization of $317.14 million and a PE ratio of -8.07. Stealth BioTherapeutics has a twelve month low of $10.70 and a twelve month high of $20.99.

An institutional investor recently bought a new position in Stealth BioTherapeutics stock. Dean Capital Investments Management LLC purchased a new position in shares of Stealth BioTherapeutics Corp (NASDAQ:MITO) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 50,420 shares of the company’s stock, valued at approximately $646,000. Dean Capital Investments Management LLC owned 0.18% of Stealth BioTherapeutics as of its most recent SEC filing. 1.09% of the stock is currently owned by institutional investors.

Stealth BioTherapeutics Company Profile

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.

Recommended Story: Dow Jones Industrial Average (DJIA)

Get a free copy of the Zacks research report on Stealth BioTherapeutics (MITO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with's FREE daily email newsletter.